Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration

Author(s): Sang Woo Kim, Jong Eun Woo, Yo Sep Yoon, Seunghwan Lee, Je Moon Woo, Jung Kee Min*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 2 , 2019


Abstract:

Objective: To investigate changes in retinal nerve fiber layer, ganglion cell-inner plexiform layer, and choroidal thickness in the macular area in patients with neovascular age-related macular degeneration who received repeated intravitreal ranibizumab and aflibercept treatments.

Methods: This retrospective study included 90 eyes of 90 treatment-naive patients. Fifty eyes were treated with intravitreal injections of aflibercept, and 40 were treated with intravitreal injections of ranibizumab. Unaffected fellow eyes (71 eyes) were used as controls. The dosage was one injection per month for 3 consecutive months as an initial treatment. The patients were examined monthly for 6 months following the initial injection. Additional intravitreal injections were given reactively in an optical coherence tomography-guided “pro re nata” protocol. Measurements of the retinal nerve fiber layer, ganglion cell-inner plexiform layer, full retina, and choroidal thickness were simultaneously obtained via swept-source optical coherence tomography in the nine Early Treatment Diabetic Retinopathy Study subfields.

Results: The retinal nerve fiber layer thickness in the nine Early Treatment Diabetic Retinopathy Study subfields did not differ significantly among the three study groups (aflibercept vs. ranibizumab vs. control). The ganglion cell-inner plexiform layer thickness was significantly reduced in the aflibercept group, while the choroidal thickness was reduced in both the aflibercept and ranibizumab groups.

Conclusion: Excessive long-term vascular endothelial growth factor inhibition by an anti-vascular endothelial growth factor agent that is trapped by neuronal and retinal pigment epithelium cells may adversely affect the function of physiological vascular endothelial growth factor and harm retinal cells and vessels.

Keywords: Aflibercept, choroid, ganglion cell-inner plexiform layer, neovascular age-related macular degeneration, ranibizumab, vascular endothelial growth factor.

[1]
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1-29.
[2]
Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154-62.
[3]
Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 2001; 158: 1161-72.
[4]
Lambert NG, Elshelmani H, Singh MK, et al. Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res 2016; 54: 64-102.
[5]
Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 113: e631-634.
[6]
Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014; 121: 2181-92.
[7]
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-48.
[8]
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
[9]
Cho HJ, Yoo SG, Kim HS, et al. Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 2015; 159: 285-292.e281.
[10]
Kim JH, Lee TG, Chang YS, Kim CG, Cho SW. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study. Br J Ophthalmol 2016; 100: 1634-9.
[11]
Koizumi H, Kano M, Yamamoto A, et al. Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration. Am J Ophthalmol 2015; 159: 627-33.
[12]
Beck M, Munk MR, Ebneter A, Wolf S, Zinkernagel MS. Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Am J Ophthalmol 2016; 167: 10-7.
[13]
Demirel S, Batioglu F, Ozmert E, Erenler F. The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration. Curr Eye Res 2015; 40: 87-92.
[14]
Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, et al. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 2012; 53: 6214-8.
[15]
Parlak M, Oner FH, Saatci AO. The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. Int Ophthalmol 2015; 35: 473-80.
[16]
Perdicchi A, Peluso G, Iacovello D, et al. Ganglion cell complex evaluation in exudative age-related macular degeneration after repeated intravitreal injections of ranibizumab. Biomed Res Int 2015; 2015268796
[17]
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014; 98: 1636-41.
[18]
Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 2014; 98: 813-25.
[19]
McKibbin M, Devonport H, Gale R, et al. Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye (Lond) 2015; 29(Suppl. 1): S1-S11.
[20]
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014; 121: 193-201.
[21]
Mansouri K, Medeiros FA, Tatham AJ, Marchase N, Weinreb RN. Evaluation of retinal and choroidal thickness by swept-source optical coherence tomography: repeatabliliy and assessment of artifacts. Am J Ophthalmol 2014; 157: 1022-32.
[22]
Lee HJ, Kim MS, Jo YJ, Kim JY. Ganglion Cell-Inner Plexiform Layer Thickness in Retinal Diseases: Repeatability Study of Spectral-Domain Optical Coherence Tomography. Am J Ophthalmol 2015; 160: 283-9.
[23]
Shin IH, Lee WH, Lee JJ, Jo YJ, Kim JY. Thickness of the macula, retinal nerve fiber layer, and ganglion cell-inner plexiform layer in the age-related macula degeneration: The Repeatability Study of Sectral Domain Optical Coherence Tomography. Retina 2018; 38: 253-62.
[24]
Schraermeyer U, Julien S. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol 2013; 250: 1303-13.
[25]
Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005; 167: 1451-9.
[26]
Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D’Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA 2009; 106: 18751-6.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 2
Year: 2019
Page: [184 - 189]
Pages: 6
DOI: 10.2174/1381612825666190319165824
Price: $65

Article Metrics

PDF: 24
HTML: 5
PRC: 1

Special-new-year-discount